tadalafil has been researched along with Hypertrophy in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Ikeda, T; Katsuragi, S; Kawamura, T; Maki, S; Tachibana, R; Takeuchi, H; Tanaka, H; Tanaka, K; Toriyabe, K; Yoshikawa, K | 1 |
Kass, DA | 1 |
1 review(s) available for tadalafil and Hypertrophy
Article | Year |
---|---|
Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.
Topics: Carbolines; Cardiomyopathy, Dilated; Cyclic AMP; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Fibrosis; Heart; Heart Failure; Humans; Hypertrophy; Myocardium; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Transforming Growth Factor beta; TRPC Cation Channels; Ventricular Remodeling | 2012 |
1 other study(ies) available for tadalafil and Hypertrophy
Article | Year |
---|---|
Maternal tadalafil therapy for fetal growth restriction prevents non-alcoholic fatty liver disease and adipocyte hypertrophy in the offspring.
Topics: Adipocytes; Animals; Diet, High-Fat; Female; Fetal Development; Fetal Growth Retardation; Glucose Tolerance Test; Hypertension; Hypertrophy; Male; Mice; Mice, Inbred C57BL; NG-Nitroarginine Methyl Ester; Non-alcoholic Fatty Liver Disease; Pregnancy; Prenatal Exposure Delayed Effects; Tadalafil | 2021 |